Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
A Phase II Selection Design of Pharmacodynamic Separation of Carboplatin/Paclitaxel/OSI-774 (Erlotinib; NSC-718781) or OSI-774 Alone in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Performance Status 2 (PS-2)
Status: Enrolling
Updated:  1/31/2018
North Puget Oncology at United General Hospital
mi
from
Sedro-Woolley, WA
S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
A Phase II Selection Design of Pharmacodynamic Separation of Carboplatin/Paclitaxel/OSI-774 (Erlotinib; NSC-718781) or OSI-774 Alone in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Performance Status 2 (PS-2)
Status: Enrolling
Updated: 1/31/2018
North Puget Oncology at United General Hospital
mi
from
Sedro-Woolley, WA
Click here to add this to my saved trials
S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
A Phase II Selection Design of Pharmacodynamic Separation of Carboplatin/Paclitaxel/OSI-774 (Erlotinib; NSC-718781) or OSI-774 Alone in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Performance Status 2 (PS-2)
Status: Enrolling
Updated:  1/31/2018
Evergreen Hematology and Oncology, PS
mi
from
Spokane, WA
S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
A Phase II Selection Design of Pharmacodynamic Separation of Carboplatin/Paclitaxel/OSI-774 (Erlotinib; NSC-718781) or OSI-774 Alone in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Performance Status 2 (PS-2)
Status: Enrolling
Updated: 1/31/2018
Evergreen Hematology and Oncology, PS
mi
from
Spokane, WA
Click here to add this to my saved trials
S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
A Phase II Selection Design of Pharmacodynamic Separation of Carboplatin/Paclitaxel/OSI-774 (Erlotinib; NSC-718781) or OSI-774 Alone in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Performance Status 2 (PS-2)
Status: Enrolling
Updated:  1/31/2018
Cancer Care Northwest - Spokane South
mi
from
Spokane, WA
S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
A Phase II Selection Design of Pharmacodynamic Separation of Carboplatin/Paclitaxel/OSI-774 (Erlotinib; NSC-718781) or OSI-774 Alone in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Performance Status 2 (PS-2)
Status: Enrolling
Updated: 1/31/2018
Cancer Care Northwest - Spokane South
mi
from
Spokane, WA
Click here to add this to my saved trials
S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
A Phase II Selection Design of Pharmacodynamic Separation of Carboplatin/Paclitaxel/OSI-774 (Erlotinib; NSC-718781) or OSI-774 Alone in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Performance Status 2 (PS-2)
Status: Enrolling
Updated:  1/31/2018
Wenatchee Valley Medical Center
mi
from
Wenatchee, WA
S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
A Phase II Selection Design of Pharmacodynamic Separation of Carboplatin/Paclitaxel/OSI-774 (Erlotinib; NSC-718781) or OSI-774 Alone in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Performance Status 2 (PS-2)
Status: Enrolling
Updated: 1/31/2018
Wenatchee Valley Medical Center
mi
from
Wenatchee, WA
Click here to add this to my saved trials
S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
A Phase II Selection Design of Pharmacodynamic Separation of Carboplatin/Paclitaxel/OSI-774 (Erlotinib; NSC-718781) or OSI-774 Alone in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Performance Status 2 (PS-2)
Status: Enrolling
Updated:  1/31/2018
Rocky Mountain Oncology
mi
from
Casper, WY
S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
A Phase II Selection Design of Pharmacodynamic Separation of Carboplatin/Paclitaxel/OSI-774 (Erlotinib; NSC-718781) or OSI-774 Alone in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Performance Status 2 (PS-2)
Status: Enrolling
Updated: 1/31/2018
Rocky Mountain Oncology
mi
from
Casper, WY
Click here to add this to my saved trials
S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
A Phase II Selection Design of Pharmacodynamic Separation of Carboplatin/Paclitaxel/OSI-774 (Erlotinib; NSC-718781) or OSI-774 Alone in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Performance Status 2 (PS-2)
Status: Enrolling
Updated:  1/31/2018
USC/Norris Comprehensive Cancer Center and Hospital
mi
from
Los Angeles, CA
S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
A Phase II Selection Design of Pharmacodynamic Separation of Carboplatin/Paclitaxel/OSI-774 (Erlotinib; NSC-718781) or OSI-774 Alone in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Performance Status 2 (PS-2)
Status: Enrolling
Updated: 1/31/2018
USC/Norris Comprehensive Cancer Center and Hospital
mi
from
Los Angeles, CA
Click here to add this to my saved trials
S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
A Phase II Selection Design of Pharmacodynamic Separation of Carboplatin/Paclitaxel/OSI-774 (Erlotinib; NSC-718781) or OSI-774 Alone in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Performance Status 2 (PS-2)
Status: Enrolling
Updated:  1/31/2018
Sutter Health - Western Division Cancer Research Group
mi
from
Novato, CA
S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
A Phase II Selection Design of Pharmacodynamic Separation of Carboplatin/Paclitaxel/OSI-774 (Erlotinib; NSC-718781) or OSI-774 Alone in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Performance Status 2 (PS-2)
Status: Enrolling
Updated: 1/31/2018
Sutter Health - Western Division Cancer Research Group
mi
from
Novato, CA
Click here to add this to my saved trials
S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
A Phase II Selection Design of Pharmacodynamic Separation of Carboplatin/Paclitaxel/OSI-774 (Erlotinib; NSC-718781) or OSI-774 Alone in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Performance Status 2 (PS-2)
Status: Enrolling
Updated:  1/31/2018
Kaiser Permanente Medical Center - Oakland
mi
from
Oakland, CA
S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
A Phase II Selection Design of Pharmacodynamic Separation of Carboplatin/Paclitaxel/OSI-774 (Erlotinib; NSC-718781) or OSI-774 Alone in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Performance Status 2 (PS-2)
Status: Enrolling
Updated: 1/31/2018
Kaiser Permanente Medical Center - Oakland
mi
from
Oakland, CA
Click here to add this to my saved trials
S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
A Phase II Selection Design of Pharmacodynamic Separation of Carboplatin/Paclitaxel/OSI-774 (Erlotinib; NSC-718781) or OSI-774 Alone in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Performance Status 2 (PS-2)
Status: Enrolling
Updated:  1/31/2018
Kaiser Permanente Medical Center - Santa Clara Kiely Campus
mi
from
Santa Clara, CA
S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
A Phase II Selection Design of Pharmacodynamic Separation of Carboplatin/Paclitaxel/OSI-774 (Erlotinib; NSC-718781) or OSI-774 Alone in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Performance Status 2 (PS-2)
Status: Enrolling
Updated: 1/31/2018
Kaiser Permanente Medical Center - Santa Clara Kiely Campus
mi
from
Santa Clara, CA
Click here to add this to my saved trials
S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
A Phase II Selection Design of Pharmacodynamic Separation of Carboplatin/Paclitaxel/OSI-774 (Erlotinib; NSC-718781) or OSI-774 Alone in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Performance Status 2 (PS-2)
Status: Enrolling
Updated:  1/31/2018
Mountain States Tumor Institute at St. Luke's Regional Medical Center
mi
from
Boise, ID
S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
A Phase II Selection Design of Pharmacodynamic Separation of Carboplatin/Paclitaxel/OSI-774 (Erlotinib; NSC-718781) or OSI-774 Alone in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Performance Status 2 (PS-2)
Status: Enrolling
Updated: 1/31/2018
Mountain States Tumor Institute at St. Luke's Regional Medical Center
mi
from
Boise, ID
Click here to add this to my saved trials
S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
A Phase II Selection Design of Pharmacodynamic Separation of Carboplatin/Paclitaxel/OSI-774 (Erlotinib; NSC-718781) or OSI-774 Alone in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Performance Status 2 (PS-2)
Status: Enrolling
Updated:  1/31/2018
Saint Luke's Mountain States Tumor Institute
mi
from
Nampa, ID
S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
A Phase II Selection Design of Pharmacodynamic Separation of Carboplatin/Paclitaxel/OSI-774 (Erlotinib; NSC-718781) or OSI-774 Alone in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Performance Status 2 (PS-2)
Status: Enrolling
Updated: 1/31/2018
Saint Luke's Mountain States Tumor Institute
mi
from
Nampa, ID
Click here to add this to my saved trials
S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
A Phase II Selection Design of Pharmacodynamic Separation of Carboplatin/Paclitaxel/OSI-774 (Erlotinib; NSC-718781) or OSI-774 Alone in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Performance Status 2 (PS-2)
Status: Enrolling
Updated:  1/31/2018
Foote Memorial Hospital
mi
from
Jackson, MI
S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
A Phase II Selection Design of Pharmacodynamic Separation of Carboplatin/Paclitaxel/OSI-774 (Erlotinib; NSC-718781) or OSI-774 Alone in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Performance Status 2 (PS-2)
Status: Enrolling
Updated: 1/31/2018
Foote Memorial Hospital
mi
from
Jackson, MI
Click here to add this to my saved trials
S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
A Phase II Selection Design of Pharmacodynamic Separation of Carboplatin/Paclitaxel/OSI-774 (Erlotinib; NSC-718781) or OSI-774 Alone in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Performance Status 2 (PS-2)
Status: Enrolling
Updated:  1/31/2018
St. John Macomb Hospital
mi
from
Warren, MI
S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
A Phase II Selection Design of Pharmacodynamic Separation of Carboplatin/Paclitaxel/OSI-774 (Erlotinib; NSC-718781) or OSI-774 Alone in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Performance Status 2 (PS-2)
Status: Enrolling
Updated: 1/31/2018
St. John Macomb Hospital
mi
from
Warren, MI
Click here to add this to my saved trials
S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
A Phase II Selection Design of Pharmacodynamic Separation of Carboplatin/Paclitaxel/OSI-774 (Erlotinib; NSC-718781) or OSI-774 Alone in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Performance Status 2 (PS-2)
Status: Enrolling
Updated:  1/31/2018
St. John's Regional Health Center
mi
from
Springfield, MO
S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
A Phase II Selection Design of Pharmacodynamic Separation of Carboplatin/Paclitaxel/OSI-774 (Erlotinib; NSC-718781) or OSI-774 Alone in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Performance Status 2 (PS-2)
Status: Enrolling
Updated: 1/31/2018
St. John's Regional Health Center
mi
from
Springfield, MO
Click here to add this to my saved trials
S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
A Phase II Selection Design of Pharmacodynamic Separation of Carboplatin/Paclitaxel/OSI-774 (Erlotinib; NSC-718781) or OSI-774 Alone in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Performance Status 2 (PS-2)
Status: Enrolling
Updated:  1/31/2018
CCOP - Montana Cancer Consortium
mi
from
Billings, MT
S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
A Phase II Selection Design of Pharmacodynamic Separation of Carboplatin/Paclitaxel/OSI-774 (Erlotinib; NSC-718781) or OSI-774 Alone in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Performance Status 2 (PS-2)
Status: Enrolling
Updated: 1/31/2018
CCOP - Montana Cancer Consortium
mi
from
Billings, MT
Click here to add this to my saved trials
S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
A Phase II Selection Design of Pharmacodynamic Separation of Carboplatin/Paclitaxel/OSI-774 (Erlotinib; NSC-718781) or OSI-774 Alone in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Performance Status 2 (PS-2)
Status: Enrolling
Updated:  1/31/2018
Billings Clinic - Downtown
mi
from
Billings, MT
S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
A Phase II Selection Design of Pharmacodynamic Separation of Carboplatin/Paclitaxel/OSI-774 (Erlotinib; NSC-718781) or OSI-774 Alone in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Performance Status 2 (PS-2)
Status: Enrolling
Updated: 1/31/2018
Billings Clinic - Downtown
mi
from
Billings, MT
Click here to add this to my saved trials
S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
A Phase II Selection Design of Pharmacodynamic Separation of Carboplatin/Paclitaxel/OSI-774 (Erlotinib; NSC-718781) or OSI-774 Alone in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Performance Status 2 (PS-2)
Status: Enrolling
Updated:  1/31/2018
Great Falls Clinic - Main Facility
mi
from
Great Falls, MT
S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
A Phase II Selection Design of Pharmacodynamic Separation of Carboplatin/Paclitaxel/OSI-774 (Erlotinib; NSC-718781) or OSI-774 Alone in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Performance Status 2 (PS-2)
Status: Enrolling
Updated: 1/31/2018
Great Falls Clinic - Main Facility
mi
from
Great Falls, MT
Click here to add this to my saved trials
S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
A Phase II Selection Design of Pharmacodynamic Separation of Carboplatin/Paclitaxel/OSI-774 (Erlotinib; NSC-718781) or OSI-774 Alone in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Performance Status 2 (PS-2)
Status: Enrolling
Updated:  1/31/2018
Montana Cancer Specialists at Montana Cancer Center
mi
from
Missoula, MT
S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
A Phase II Selection Design of Pharmacodynamic Separation of Carboplatin/Paclitaxel/OSI-774 (Erlotinib; NSC-718781) or OSI-774 Alone in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Performance Status 2 (PS-2)
Status: Enrolling
Updated: 1/31/2018
Montana Cancer Specialists at Montana Cancer Center
mi
from
Missoula, MT
Click here to add this to my saved trials
S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
A Phase II Selection Design of Pharmacodynamic Separation of Carboplatin/Paclitaxel/OSI-774 (Erlotinib; NSC-718781) or OSI-774 Alone in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Performance Status 2 (PS-2)
Status: Enrolling
Updated:  1/31/2018
Wayne Memorial Hospital, Incorporated
mi
from
Goldsboro, NC
S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
A Phase II Selection Design of Pharmacodynamic Separation of Carboplatin/Paclitaxel/OSI-774 (Erlotinib; NSC-718781) or OSI-774 Alone in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Performance Status 2 (PS-2)
Status: Enrolling
Updated: 1/31/2018
Wayne Memorial Hospital, Incorporated
mi
from
Goldsboro, NC
Click here to add this to my saved trials
S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
A Phase II Selection Design of Pharmacodynamic Separation of Carboplatin/Paclitaxel/OSI-774 (Erlotinib; NSC-718781) or OSI-774 Alone in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Performance Status 2 (PS-2)
Status: Enrolling
Updated:  1/31/2018
Columbia Basin Hematology
mi
from
Kennewick, WA
S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
A Phase II Selection Design of Pharmacodynamic Separation of Carboplatin/Paclitaxel/OSI-774 (Erlotinib; NSC-718781) or OSI-774 Alone in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Performance Status 2 (PS-2)
Status: Enrolling
Updated: 1/31/2018
Columbia Basin Hematology
mi
from
Kennewick, WA
Click here to add this to my saved trials
Chemoimmunotherapy and Radiation in Pancreatic Cancer
Phase I Trial of Chemoimmunotherapy and Hypofractionated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma.
Status: Enrolling
Updated:  1/31/2018
Portland Providence Medical Center
mi
from
Portland, OR
Chemoimmunotherapy and Radiation in Pancreatic Cancer
Phase I Trial of Chemoimmunotherapy and Hypofractionated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma.
Status: Enrolling
Updated: 1/31/2018
Portland Providence Medical Center
mi
from
Portland, OR
Click here to add this to my saved trials
An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary Objective
An Open Label, Multi-center, Extension Study to Evaluate Long-term Safety and Tolerability of Dovitinib in Patients With Solid Tumors, Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored, Single Agent Dovitinib Studies, Which Have Fulfilled the Requirements for the Primary Objective, and Are Benefitting From Continued Dovitinib Treatment as Assessed by the Investigator
Status: Enrolling
Updated:  1/31/2018
Novartis Investigative Site
mi
from
Salzburg,
An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary Objective
An Open Label, Multi-center, Extension Study to Evaluate Long-term Safety and Tolerability of Dovitinib in Patients With Solid Tumors, Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored, Single Agent Dovitinib Studies, Which Have Fulfilled the Requirements for the Primary Objective, and Are Benefitting From Continued Dovitinib Treatment as Assessed by the Investigator
Status: Enrolling
Updated: 1/31/2018
Novartis Investigative Site
mi
from
Salzburg,
Click here to add this to my saved trials
An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary Objective
An Open Label, Multi-center, Extension Study to Evaluate Long-term Safety and Tolerability of Dovitinib in Patients With Solid Tumors, Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored, Single Agent Dovitinib Studies, Which Have Fulfilled the Requirements for the Primary Objective, and Are Benefitting From Continued Dovitinib Treatment as Assessed by the Investigator
Status: Enrolling
Updated:  1/31/2018
Novartis Investigative Site
mi
from
Las Vegas, NV
An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary Objective
An Open Label, Multi-center, Extension Study to Evaluate Long-term Safety and Tolerability of Dovitinib in Patients With Solid Tumors, Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored, Single Agent Dovitinib Studies, Which Have Fulfilled the Requirements for the Primary Objective, and Are Benefitting From Continued Dovitinib Treatment as Assessed by the Investigator
Status: Enrolling
Updated: 1/31/2018
Novartis Investigative Site
mi
from
Las Vegas, NV
Click here to add this to my saved trials
An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary Objective
An Open Label, Multi-center, Extension Study to Evaluate Long-term Safety and Tolerability of Dovitinib in Patients With Solid Tumors, Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored, Single Agent Dovitinib Studies, Which Have Fulfilled the Requirements for the Primary Objective, and Are Benefitting From Continued Dovitinib Treatment as Assessed by the Investigator
Status: Enrolling
Updated:  1/31/2018
Novartis Investigative Site
mi
from
Bronx, NY
An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary Objective
An Open Label, Multi-center, Extension Study to Evaluate Long-term Safety and Tolerability of Dovitinib in Patients With Solid Tumors, Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored, Single Agent Dovitinib Studies, Which Have Fulfilled the Requirements for the Primary Objective, and Are Benefitting From Continued Dovitinib Treatment as Assessed by the Investigator
Status: Enrolling
Updated: 1/31/2018
Novartis Investigative Site
mi
from
Bronx, NY
Click here to add this to my saved trials
Neoadjuvant Propanolol in Breast Cancer
Pilot "Window of Opportunity" Neoadjuvant Study of Propranolol in Breast Cancer
Status: Enrolling
Updated:  1/31/2018
Texas Tech University HSC
mi
from
El Paso, TX
Neoadjuvant Propanolol in Breast Cancer
Pilot "Window of Opportunity" Neoadjuvant Study of Propranolol in Breast Cancer
Status: Enrolling
Updated: 1/31/2018
Texas Tech University HSC
mi
from
El Paso, TX
Click here to add this to my saved trials
Weekly IV Topotecan and Cisplatin With Radiation in Cervical Carcinoma
A Pilot Study of Weekly IV Topotecan and Cisplatin With Concurrent Pelvic Radiation in the Treatment of Stages IB2 - IVA Cervical Carcinoma
Status: Enrolling
Updated:  2/1/2018
Chao Family Comprehensive Cancer Center
mi
from
Orange, CA
Weekly IV Topotecan and Cisplatin With Radiation in Cervical Carcinoma
A Pilot Study of Weekly IV Topotecan and Cisplatin With Concurrent Pelvic Radiation in the Treatment of Stages IB2 - IVA Cervical Carcinoma
Status: Enrolling
Updated: 2/1/2018
Chao Family Comprehensive Cancer Center
mi
from
Orange, CA
Click here to add this to my saved trials
Neo-Adjuvant FOLFOX for Rectal Carcinoma
A Phase II Open- Labeled, Prospective Study to Determine the Efficacy of Pre- Operative Chemotherapy With Six Cycles of Modified FOLFOX 6 Followed by Total Mesorectal Excision (TME) Followed by an Additional Six Cycles of FOLFOX 6
Status: Enrolling
Updated:  2/1/2018
Beth Israel Med Ctr
mi
from
New York, NY
Neo-Adjuvant FOLFOX for Rectal Carcinoma
A Phase II Open- Labeled, Prospective Study to Determine the Efficacy of Pre- Operative Chemotherapy With Six Cycles of Modified FOLFOX 6 Followed by Total Mesorectal Excision (TME) Followed by an Additional Six Cycles of FOLFOX 6
Status: Enrolling
Updated: 2/1/2018
Beth Israel Med Ctr
mi
from
New York, NY
Click here to add this to my saved trials
Neo-Adjuvant FOLFOX for Rectal Carcinoma
A Phase II Open- Labeled, Prospective Study to Determine the Efficacy of Pre- Operative Chemotherapy With Six Cycles of Modified FOLFOX 6 Followed by Total Mesorectal Excision (TME) Followed by an Additional Six Cycles of FOLFOX 6
Status: Enrolling
Updated:  2/1/2018
St Luke's - Roosevelt Hospital Center
mi
from
New York, NY
Neo-Adjuvant FOLFOX for Rectal Carcinoma
A Phase II Open- Labeled, Prospective Study to Determine the Efficacy of Pre- Operative Chemotherapy With Six Cycles of Modified FOLFOX 6 Followed by Total Mesorectal Excision (TME) Followed by an Additional Six Cycles of FOLFOX 6
Status: Enrolling
Updated: 2/1/2018
St Luke's - Roosevelt Hospital Center
mi
from
New York, NY
Click here to add this to my saved trials
Radiation Therapy for Rising Prostate Specific Antigen (PSA) Post-prostatectomy
Radiation Therapy for Rising Prostate Specific Antigen (PSA) Post-prostatectomy
Status: Enrolling
Updated:  2/1/2018
Kaseman Presbyterian Hospital
mi
from
Albuquerque, NM
Radiation Therapy for Rising Prostate Specific Antigen (PSA) Post-prostatectomy
Radiation Therapy for Rising Prostate Specific Antigen (PSA) Post-prostatectomy
Status: Enrolling
Updated: 2/1/2018
Kaseman Presbyterian Hospital
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Radiation Therapy for Rising Prostate Specific Antigen (PSA) Post-prostatectomy
Radiation Therapy for Rising Prostate Specific Antigen (PSA) Post-prostatectomy
Status: Enrolling
Updated:  2/1/2018
Spartanburg Regional Healthcare System
mi
from
Spartanburg, SC
Radiation Therapy for Rising Prostate Specific Antigen (PSA) Post-prostatectomy
Radiation Therapy for Rising Prostate Specific Antigen (PSA) Post-prostatectomy
Status: Enrolling
Updated: 2/1/2018
Spartanburg Regional Healthcare System
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Radiation Therapy for Rising Prostate Specific Antigen (PSA) Post-prostatectomy
Radiation Therapy for Rising Prostate Specific Antigen (PSA) Post-prostatectomy
Status: Enrolling
Updated:  2/1/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Radiation Therapy for Rising Prostate Specific Antigen (PSA) Post-prostatectomy
Radiation Therapy for Rising Prostate Specific Antigen (PSA) Post-prostatectomy
Status: Enrolling
Updated: 2/1/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Intraoperative Imaging of Breast Cancer With Indocyanine Green
A Phase 0/1, Open-Label, Single Center Study of the Imaging Potential of Indocyanine Green in Subject Undergoing Breast Cancer Surgery
Status: Enrolling
Updated:  2/1/2018
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Intraoperative Imaging of Breast Cancer With Indocyanine Green
A Phase 0/1, Open-Label, Single Center Study of the Imaging Potential of Indocyanine Green in Subject Undergoing Breast Cancer Surgery
Status: Enrolling
Updated: 2/1/2018
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable GIST
A Non-randomized, Open-label Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) Progressing After Prior Therapy With Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  2/1/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable GIST
A Non-randomized, Open-label Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) Progressing After Prior Therapy With Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 2/1/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of LY3022855 In Participants With Breast or Prostate Cancer
Phase 1 Study to Identify the Immunomodulatory Activity of LY3022855 (IMC-CS4) in Patients With Advanced, Refractory Breast or Prostate Cancer
Status: Enrolling
Updated:  2/1/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
A Study of LY3022855 In Participants With Breast or Prostate Cancer
Phase 1 Study to Identify the Immunomodulatory Activity of LY3022855 (IMC-CS4) in Patients With Advanced, Refractory Breast or Prostate Cancer
Status: Enrolling
Updated: 2/1/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
A Study of LY3022855 In Participants With Breast or Prostate Cancer
Phase 1 Study to Identify the Immunomodulatory Activity of LY3022855 (IMC-CS4) in Patients With Advanced, Refractory Breast or Prostate Cancer
Status: Enrolling
Updated:  2/1/2018
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
A Study of LY3022855 In Participants With Breast or Prostate Cancer
Phase 1 Study to Identify the Immunomodulatory Activity of LY3022855 (IMC-CS4) in Patients With Advanced, Refractory Breast or Prostate Cancer
Status: Enrolling
Updated: 2/1/2018
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Vessel Sparing Prostate Radiation Therapy
Vessel Sparing Prostate Radiation Therapy: Dose Limitation to Critical Erectile Structures (Corpus Cavernosum and Internal Pudendal Artery) by MRI Based Treatment Planning
Status: Enrolling
Updated:  2/1/2018
University of Michigan
mi
from
Ann Arbor, MI
Vessel Sparing Prostate Radiation Therapy
Vessel Sparing Prostate Radiation Therapy: Dose Limitation to Critical Erectile Structures (Corpus Cavernosum and Internal Pudendal Artery) by MRI Based Treatment Planning
Status: Enrolling
Updated: 2/1/2018
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Evaluation of Respiratory Motion-Corrected Cone-Beam CT in Radiation Treatment of Thoracic and Abdominal Cancers
Evaluation of Respiratory Motion-Corrected Cone-Beam CT in Radiation Treatment of Thoracic and Abdominal Cancers
Status: Enrolling
Updated:  2/2/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Evaluation of Respiratory Motion-Corrected Cone-Beam CT in Radiation Treatment of Thoracic and Abdominal Cancers
Evaluation of Respiratory Motion-Corrected Cone-Beam CT in Radiation Treatment of Thoracic and Abdominal Cancers
Status: Enrolling
Updated: 2/2/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using Diffuse Optical Spectroscopic Imaging
Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using Diffuse Optical Spectroscopic Imaging
Status: Enrolling
Updated:  2/2/2018
Beckman Laser Institute
mi
from
Irvine, CA
Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using Diffuse Optical Spectroscopic Imaging
Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using Diffuse Optical Spectroscopic Imaging
Status: Enrolling
Updated: 2/2/2018
Beckman Laser Institute
mi
from
Irvine, CA
Click here to add this to my saved trials
Strategies and Opportunities to Stop Colon Cancer in Priority Populations
Strategies and Opportunities to Stop Colon Cancer in Priority Populations
Status: Enrolling
Updated:  2/2/2018
Open Door Health Center
mi
from
Arcata, CA
Strategies and Opportunities to Stop Colon Cancer in Priority Populations
Strategies and Opportunities to Stop Colon Cancer in Priority Populations
Status: Enrolling
Updated: 2/2/2018
Open Door Health Center
mi
from
Arcata, CA
Click here to add this to my saved trials
Strategies and Opportunities to Stop Colon Cancer in Priority Populations
Strategies and Opportunities to Stop Colon Cancer in Priority Populations
Status: Enrolling
Updated:  2/2/2018
Mosaic Medical
mi
from
Bend, OR
Strategies and Opportunities to Stop Colon Cancer in Priority Populations
Strategies and Opportunities to Stop Colon Cancer in Priority Populations
Status: Enrolling
Updated: 2/2/2018
Mosaic Medical
mi
from
Bend, OR
Click here to add this to my saved trials
Strategies and Opportunities to Stop Colon Cancer in Priority Populations
Strategies and Opportunities to Stop Colon Cancer in Priority Populations
Status: Enrolling
Updated:  2/2/2018
Benton and Linn County Health Centers
mi
from
Corvallis, OR
Strategies and Opportunities to Stop Colon Cancer in Priority Populations
Strategies and Opportunities to Stop Colon Cancer in Priority Populations
Status: Enrolling
Updated: 2/2/2018
Benton and Linn County Health Centers
mi
from
Corvallis, OR
Click here to add this to my saved trials
Strategies and Opportunities to Stop Colon Cancer in Priority Populations
Strategies and Opportunities to Stop Colon Cancer in Priority Populations
Status: Enrolling
Updated:  2/2/2018
Virginia Garcia Memorial Health Center
mi
from
Hillsboro, OR
Strategies and Opportunities to Stop Colon Cancer in Priority Populations
Strategies and Opportunities to Stop Colon Cancer in Priority Populations
Status: Enrolling
Updated: 2/2/2018
Virginia Garcia Memorial Health Center
mi
from
Hillsboro, OR
Click here to add this to my saved trials
Strategies and Opportunities to Stop Colon Cancer in Priority Populations
Strategies and Opportunities to Stop Colon Cancer in Priority Populations
Status: Enrolling
Updated:  2/2/2018
La Clinica Health Care
mi
from
Medford, OR
Strategies and Opportunities to Stop Colon Cancer in Priority Populations
Strategies and Opportunities to Stop Colon Cancer in Priority Populations
Status: Enrolling
Updated: 2/2/2018
La Clinica Health Care
mi
from
Medford, OR
Click here to add this to my saved trials
Strategies and Opportunities to Stop Colon Cancer in Priority Populations
Strategies and Opportunities to Stop Colon Cancer in Priority Populations
Status: Enrolling
Updated:  2/2/2018
Community Health Center
mi
from
Medford, OR
Strategies and Opportunities to Stop Colon Cancer in Priority Populations
Strategies and Opportunities to Stop Colon Cancer in Priority Populations
Status: Enrolling
Updated: 2/2/2018
Community Health Center
mi
from
Medford, OR
Click here to add this to my saved trials
Strategies and Opportunities to Stop Colon Cancer in Priority Populations
Strategies and Opportunities to Stop Colon Cancer in Priority Populations
Status: Enrolling
Updated:  2/2/2018
Multnomah County Health Department
mi
from
Portland, OR
Strategies and Opportunities to Stop Colon Cancer in Priority Populations
Strategies and Opportunities to Stop Colon Cancer in Priority Populations
Status: Enrolling
Updated: 2/2/2018
Multnomah County Health Department
mi
from
Portland, OR
Click here to add this to my saved trials
Strategies and Opportunities to Stop Colon Cancer in Priority Populations
Strategies and Opportunities to Stop Colon Cancer in Priority Populations
Status: Enrolling
Updated:  2/2/2018
Oregon Health and Science University
mi
from
Scappoose, OR
Strategies and Opportunities to Stop Colon Cancer in Priority Populations
Strategies and Opportunities to Stop Colon Cancer in Priority Populations
Status: Enrolling
Updated: 2/2/2018
Oregon Health and Science University
mi
from
Scappoose, OR
Click here to add this to my saved trials
Combined Digital Colposcopy Analysis to Improve Cervical Precancer and Cancer Detection
Development and Application of a Multispectral Digital Colposcopy Algorithm for Detection of Cervical Intraepithelial Neoplasia and Neoplasia.
Status: Enrolling
Updated:  2/2/2018
Brookdale Hospital and Medical Center
mi
from
Brooklyn, NY
Combined Digital Colposcopy Analysis to Improve Cervical Precancer and Cancer Detection
Development and Application of a Multispectral Digital Colposcopy Algorithm for Detection of Cervical Intraepithelial Neoplasia and Neoplasia.
Status: Enrolling
Updated: 2/2/2018
Brookdale Hospital and Medical Center
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Combined Digital Colposcopy Analysis to Improve Cervical Precancer and Cancer Detection
Development and Application of a Multispectral Digital Colposcopy Algorithm for Detection of Cervical Intraepithelial Neoplasia and Neoplasia.
Status: Enrolling
Updated:  2/2/2018
Texas Tech Health Sciences Center
mi
from
El Paso, TX
Combined Digital Colposcopy Analysis to Improve Cervical Precancer and Cancer Detection
Development and Application of a Multispectral Digital Colposcopy Algorithm for Detection of Cervical Intraepithelial Neoplasia and Neoplasia.
Status: Enrolling
Updated: 2/2/2018
Texas Tech Health Sciences Center
mi
from
El Paso, TX
Click here to add this to my saved trials
Combined Digital Colposcopy Analysis to Improve Cervical Precancer and Cancer Detection
Development and Application of a Multispectral Digital Colposcopy Algorithm for Detection of Cervical Intraepithelial Neoplasia and Neoplasia.
Status: Enrolling
Updated:  2/2/2018
Vancouver General Hospital - Women's Clinic (G&L Diamond Centre)
mi
from
Vancouver,
Combined Digital Colposcopy Analysis to Improve Cervical Precancer and Cancer Detection
Development and Application of a Multispectral Digital Colposcopy Algorithm for Detection of Cervical Intraepithelial Neoplasia and Neoplasia.
Status: Enrolling
Updated: 2/2/2018
Vancouver General Hospital - Women's Clinic (G&L Diamond Centre)
mi
from
Vancouver,
Click here to add this to my saved trials
Prone Breath Hold Technique to Decrease Cardiac and Pulmonary Doses in Women Receiving Left Breast Radiotherapy
Pilot Study For Prone Breath Hold Technique to Decrease Cardiac and Pulmonary Doses in Women Receiving Left Breast Radiotherapy
Status: Enrolling
Updated:  2/2/2018
Radiation Oncology Department at the University of Arizona Heath Network
mi
from
Tucson, AZ
Prone Breath Hold Technique to Decrease Cardiac and Pulmonary Doses in Women Receiving Left Breast Radiotherapy
Pilot Study For Prone Breath Hold Technique to Decrease Cardiac and Pulmonary Doses in Women Receiving Left Breast Radiotherapy
Status: Enrolling
Updated: 2/2/2018
Radiation Oncology Department at the University of Arizona Heath Network
mi
from
Tucson, AZ
Click here to add this to my saved trials